Physician profile
Adina Ion
NPI 1144330119
$695.47
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.20 · 2020: $64.96 · 2021: $126 · 2022: $262 · 2023: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $134.73 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $100.16 | 2021-2022 | |
| Amgen INC. | $88.96 | 2022-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $57.11 | 2022-2023 | |
| Boston Scientific Corporation | $45.67 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.62 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $40.55 | 2019-2021 | |
| Pfizer INC. | $26.12 | 2019-2021 | |
| Abbott Laboratories | $23.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.47 | 2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $19.96 | 2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $19.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.58 | 2019 | |
| Amarin Pharma, INC. | $18.46 | 2019 | |
| Medtronic Vascular, INC. | $18.17 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.93 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adina Ion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.